Reach Us +441414719275
RP-HPLC Method for the Simultaneous Determination of Captopril and H<sub>2</sub>-Receptor Antagonist: Application to Interaction Studies | OMICS International
ISSN: 2161-0444
Medicinal Chemistry

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

RP-HPLC Method for the Simultaneous Determination of Captopril and H2-Receptor Antagonist: Application to Interaction Studies

Najma Sultan1, Safila Naveed2* and M Saeed Arayne1

1United Biotechnologies, Karachi-75290, Pakistan

2Faculty of Pharmacy, Jinnah University for Women Karachi-74600, Pakistan

*Corresponding Author:
Safila Naveed
Faculty of Pharmacy
Jinnah University for Women Karachi-74600, Pakistan
Tel: 009203002621917
Fax: (92-21)36620614
E-mail: [email protected]

Received date: April 01, 2013; Accepted date: April 23, 2013; Published date: April 25, 2013

Citation: Sultan N, Naveed S, Arayne MS (2013) RP-HPLC Method for the Simultaneous Determination of Captopril and H2-Receptor Antagonist: Application to Interaction Studies. Med chem 3:183-187. doi:10.4172/2161-0444.1000136

Copyright: © 2013 Sultan N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Medicinal Chemistry


Rapid, sensitive, simple and accurate high-performance liquid chromatographic (HPLC) method is developed and validated for the simultaneous determination of captopril with H2 receptor antagonists as cimetidine, ranitidine and famotidine. Captopril was separated from H2 receptor antagonist using pre packed Purospher star C18 (5 μm, 25×0.46 cm) column methanol: water (60:40 v/v) were used as the mobile phase, pH 3.0 ± 0.02 was adjusted by orthophosphoric acid. The flow rate was 0.8 mLmin-1 at ambient temperature, diluent was 50:50 methanol water while UV detection was performed at 225 nm. The retention time for captopril was found to be 5.2 minute, for ranitidine and famotidine 2.5 minute and cimetidine 2.7 minute. Each drug showed a good resolution from captopril. In vitro interaction studies of captopril with commonly administered H2 receptor antagonists i.e. cimetidine, ranitidine and famotidine were carried out at 37°C using above validated method. These studies clearly indicated that H2-receptor antagonists bind to captopril causing drastic changes in the availability of the drug.


Captopril; H2-receptor antagonists; RP-HPLC; Interaction studies


Captopril (Figure 1) (2S)-3-mercapto-2-methyl-1-oxo-proptonyl]- L-proline [1], the first orally active and specific inhibitor of angiotensinconverting enzyme. It blocks the conversion of angiotensin I to angiotensin II by inhibiting the angiotensin converting enzyme and inactivates bradykinin, a potent vasodilator. The hypotensive activity of captopril probably results both from inhibitory action on reninangiotensin system and simulating action on kallikerin-kinin system [2]. Various instrumental methods have been developed for the determination of captopril by HPLC [3-6] and Spectrophotometry [7].


Figure 1: Structure of Captopril.

Histamine H2 antagonists cimetidine (CIM), ranitidine (RAN), and famotidine (FAM) classified as class III drugs (high solubility, low permeability) according to the Biopharmaceutics Classification System (BCS) [8,9] are used in the treatment of gastro-esophageal reflux disease and gastric and duodenal ulceration [10]. Several methods have been reported for the determination of ranitidine and/or cimetidine in pharmaceutical preparations using high performance liquid chromatography (HPLC) [11-13]. Number of HPLC-UV methods has been reported for the analysis of individual H2 antagonist’s cimetidine [14,15], famotidine [16,17], and ranitidine[18] in biological samples comprising urine or urine and plasma. But our method use simple methanol water 60:40 and all drugs elute out same mobile phase within 5.5 min without interference of excepients.

However, no simultaneous method for determination of both the drugs in active, in dosage formulations and in human serum has been studied so far. It is reported that Hypertension and gastrointestinal disorders are two common co-existing conditions, therefore H2- receptor antagonists and antiarrhythmic agents like calcium channel blockers, ACE Inhibitors may be administered to patients to cure hypertension with GIT problems. Co administration of H2 receptor antagonists and cardiovascular drugs are described in number of cases [19,20]. On this basis, it became apparent to develop and validate for the first time a simultaneous method for the estimation of these drugs in bulk material, dosage formulations and in human serum which can be used for therapeutic monitoring in clinical practice. The method was validated according to ICH guidelines and was found to be reproducible. Further, this validated method was used to study the possible in vitro interactions of captopril with H2-receptor antagonists (cimetidine, ranitidine and famotidine). Proposed method was selective, precise and accurate, therefore can be used for routine, quality control and clinical study and there is no limitation for it is used.



Reference standard of captopril was obtained from Squib Pharmaceutical Laboratories Pakistan. H2 receptor antagonist cimetidine (Tagamet 200 mg), ranitidine (H2-REC 150 mg) and famotidine (Famopsin 40 mg) were of Park Davis (Pvt.), Smith Kline Beecham (Pvt.) Ltd. and Remedica Ltd. Karachi Pakistan, respectively. Methanol used was of HPLC grade and all the reagents used were of analytical grade. Solutions of the compounds were prepared in methanol: water in the ratio of 60:40 v/v. These solutions were daily prepared fresh. Double distilled Deionized water was used through out the experiment which was degassed by sonicator and filtered through 0.45 μm filter paper.


Shimadzu HPLC system equipped with LC-10 AT VP pump, DGU-14 AM on-line degasser, Rheodyne manual injector fitted with a 20 μL loop, and SPD-10 A VP UV–VIS detector was utilized. Chromatographic system was integrated via Shimadzu model CBM-102 Communication Bus Module Separation was achieved on a Purospher Start C18 (250 cm × 4.6 mm, 5 μm) column and Supelco C18 (25 cm × 4.6 mm, 5 μm) column, for ruggedness studies was used Shimadzu CLASS-GC software (Version 5.03) was used for data acquisition and mathematical calculations.

Preparation of stock and working solutions

Stock solutions of 100 μgmL-1 of captopril, cimitidine, famotidine and ranitidine were prepared individually by dissolving 10 mg of each drug in 100 mL volumetric flask using 50:50 methanol water. Aliquots were diluted in the range of 0.7-12.50 μgmL-1 for H2-receptor antagonist and for captopril 9.37-150 μgmL-1. These solutions were stored at 20°C, they were prepared once and analyzed daily for inter-day and interoperator variations of the method and analyzed each time before drug analysis in biological samples. 20 μL of these solutions were injected into LC system and chromatographed.

Sample preparation

To determine the content of the drugs in the formulations, 20 tablets of each drug were powdered and powder equivalent to 10 mg of captopril, 10 mg of H2 antagonists (cimetidine, famotidine and ranitidine) were weighed, the solutions were transferred to 100 mL volumetric flask and were diluted with 50:50 v\v aqueous methanol. The resulting solutions were filtered and analyzed for the drug content. A placebo tablet was also subjected to the same process as discussed above.

Drug serum solutions

Blood samples were collected from healthy volunteers and immediately centrifuged at 3,000 rpm for 10 min. The supernatant obtained was stored at -20°C. After thawing, serum was deproteinated by addition of acetonitrile and spiked daily with working solutions to furnish the desired concentrations of captopril and the H2 receptor antagonist to get the final concentrations ranging from 0.7-12.50 μgmL-1 for H2 receptor antagonist and for captopril 9.37-150 μgmL-1.

In-vitro interaction studies

Procedure: The interaction studies were performed by preparing 200 μgmL-1 stock solutions of each drug. 20 mL of stock solution of captopril was added 20 mL of stock solution of cimetidine in a conical flask and heated on a water bath at 37°C for 3 hours. The samples were withdrawn after every half an hour interval and were analyzed on HPLC. Peak areas were recorded and degree of interactions was evaluated.

Results and Discussion

Various ratios (80:20, 70:30, 50:50 v/v) of mobile phase were tested as starting solvent for system suitability studies. The variation in the mobile phase leads to considerable changes in the chromatographic parameters, like peak symmetry and retention time. However, the ratio of (60:40 v/v) yielded best results. The pH effect showed that optimized conditions are reached when the pH value is 3 producing well resolved and sharp peaks for all drugs assayed using wavelength 225 nm (isobetic point Figure 2).


Figure 2: UV-visible spectra of Captopril and H2 receptor antagonist.

The method for the determination of captopril in raw material and dosage formulations was validated for the parameters like specificity, range and linearity, inter-assay accuracy and precision, detection and quantitation limit, robustness according to the guidelines provided by ICH. Moreover, method was also subjected to study the in vitro interactions of drugs.

Method validation

For validation of analytical methods, the guidelines of the International Conference on the Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) [21] have recommended the accomplishment of the method.

Range and linearity

To establish linearity of the proposed method, five separate series of solutions of the drug were prepared and analyzed. Standard curves were constructed at concentrations 0.78, 1.56, 3.1, 6.25 and 12.50 μgmL-1 for cimetidine, famotidine and ranitidine. Captopril 9.3, 18.8, 37.5, 75 and 150 μgmL-1. The standard calibration curves were shown to be linear in the above mentioned range in human serum. Curves were obtained by plotting the peak area against concentrations of these drugs. Linear calibration curves were generated by linear regression analysis and obtained over the respective standard concentrations ranges. The standard curve, slope, intercept and the correlation coefficient were determined. The regression statistics are shown in table 1.

Drugs Regression equations R2 LOD* ng/mL LOQ** ng/mL
Captopril y = 1883.8x - 1856.6 0.9993 1.75 5.3
Famotidine y = 21249x + 2854.7 0.9995 0.15 0.47
Cimetidine y = 27570x - 1123 0.9999 0.12 0.36
Ranitidine y = 17239x - 1479.9 0.9995 0.3 0.9

Table 1: Regression statistics LOD and LOQ.

Limit of detection (LOD) and quantitation (LOQ)

The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value. The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The LOD and LOQ values for captopril and H2-recepter antagonist for bulk material, pharmaceutical preparation and in serum were determined and are presented in table 1.


The accuracy of the method was calculated at three concentration levels (80, 100 and 120%) by spiking known quantities of the drug analytes. Three injections of each solution were injected to HPLC system and % recovery was calculated in each case.


For the precision of the method, six replicates of each level were injected to system on two different non-consecutive days in each case and % RSD was calculated. The results of accuracy and precision (Table 2) revealed that the method was accurate for all above purposes.

Analytes Assay (spiking method) Assay in serum
Conc. µgmL-1 %RSD %Rec %RSD %Rec
CAP 8 0.002 100 0.02 101.3
10 0.001 100.1 1.02 101
12 0.005 100 0.36 101.2
CIM 8 0 100 0.36 100.3
10 0.006 99 0.59 99.8
12 0.001 100 0.69 100.23
FAM 8 0.002 100 0.36 99.69
10 0.001 100 0.36 99.98
12 0.005 101 0.36 101.3
RAN 8 0.003 102 0.63 101.3
10 1.72 97.9 0.003 101.3
12 0.49 98 0.003 101.3

Table 2: Accuracy and precision.

Specificity and selectivity

Representative chromatograms (Figure 3) were generated to show other components that could be present in the sample matrix are resolved from the parent analytes. No change was observed in the chromatogram of captopril and H2 receptor antagonist in presence of common excepients. The specificity was also determined by injecting human plasma samples. Therefore, the proposed method is selective and specific for the drugs.


Figure 3: Representative chromatogram of (1) ranitidine (2) famotidine (3) cimetidine and (4) captopril in formulation.


Recovery values of all the drugs in formulations (Table 3) indicated that the average recoveries of all drugs did not exceed less than 99% and more than 100% which clearly indicated the suitability of the method.

        Conc injected Conc found   % Recovery
Drugs µg mL-1 µg mL-1  
Capoten 8 8.9 101.6
10 10.3 100.3
12 12.8 101.5
Famopsin 8 8 100.6
10 10.8 100.9
12 12.9 101.5
Tagament 8 8 99.9
10 10.8 100.9
12 12 100
H2-REC 8 7.9 99.7
10 10.2 100.2
12 12.9 102.1

Table 3: % Recoveries of different brands.


Recovery of all the drugs from serum was assessed by calculating the ratio of the peak areas of analyte in serum extract (Figure 4) and diluent. An average recovery of 99 ± 101% (mean ± S.D) was obtained in concentrations studied (n=5). These results (Table 4) clearly indicated the therapeutic application of this method.


Figure 4: Representative chromatogram of (a) blank plasma samples and (b) spiked plasma samples of captopril.

Time % Recovery
0 100 102 101 100
30 104 99.8 110 102
60 108 103 115 103
90 104 100 116 115
120 104 101 118 120
150 113 104 120 122
180 113 104 120 122

Table 4: Interaction studies of captopril with H2 receptor antagonist.


Ruggedness of this method was evaluated in two different labs with two different instruments. Lab 1 was in the Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy University of Karachi, while Lab 2 was in the Department of Chemistry, Faculty of Science University of Karachi. The method did not show any notable deviations in results from acceptable limits. The assay results indicated that the method was capable with high precision and it was found that the %R.S.D values did not exceed more than 2% (Table 6).

HPLC System   LC 10 LC 20
Drugs Columns Conc. (µg/mL) Conc.Found (µg/mL) Recovery (%) Conc. Found (µg/mL) Recovery (%)
CAP Purospher STAR 8 8 100 8.06 100.75
10 10 100 9.98 99.8
12 12 100 12 100
Supelco C18 8 8 100 7.9 98.75
10 9.9 99 10 100
12 12 100 12 100
CIM Purospher STAR 8 8.1 101.25 8.0 100
10 9.9 99 9.88 98.8
12 12 100 12 100
Supelco C18 8 8 100 8 100
10 10 100 10.1 101
12 12 100 12.1 100.8
FAM Purospher STAR 8 7.9 99.7 8.03 100.3
10 9.99 99.9 9.98 99.8
12 12 100 12 100
Supelco C18 8 7.99 99.8 8 100
10 10 100 10 100
12 12 100 11.9 99.1
RAN Purospher STAR 8 7.98 99.7 8 100
10 9.99 99.9 9.9 99
12 12 100 11.9 99.1
Supelco C18 8 7.9 98.7 8.0 100
10 10 100 10.9 109
12 12 100 12.2 101.6

Table 5: Ruggedness of the method.

  Level K’ T (Rs)
A: pH of mobile phase
2.8 -0.2 3.8 1.39 2.4
3 0 3.9 1.43 2.3
3.2 0.2 3.6 1.4 2.2
Mean ± S.D (n=6) 3.9 ± 0.2 1.4 ± 0.02 2.3 ± 0.1
B: Flow rate (mL/min)
0.6 -0.2 3.8 1.45 2.32
0.8 0 3.9 1.43 2.36
1.0 0.2 3.6 1.42 2.37
Mean ± S.D (n=6) 4.3 ± 0.2 1.4 ± 0.01 2.3 ± 0.0
C: Percentage of water in mobile phase (V/V)
35 -5 4.6 1.42 2.38
40 0 3.9 1.43 2.36
45 5 4.5 1.46 2.33
Mean ± S.D (n=6) 4.3 ± 0.0 1.4 ± 0.02 2.3 ± 0.0
D: Wavelength (nm)
220 -5 3.5 1.52 2.5
225 0 3.9 1.43 2.36
230 5 3.4 1.55 2.3
Mean ± S.D (n=6) 3.3 ± 0.1 1.5 ± 0.0 2.4 ± 0.1

Table 6: Robustness of the method for captopril (n=6).


Robustness was evaluated by slight changes in pH levels of mobile phase and flow rates. Peak areas of all the drugs were recorded in each case and coefficient of variance was calculated for it which is given in table 6.

In-vitro interaction studies

Due to short analysis time, suitability for routine analysis and for control purposes in pharmaceutical dosage forms and good recovery values in serum as well the present method was employed to study in vitro interactions of captopril with H2-blockers in presence of each other. As concerns the choice of drugs, these drugs have been selected for their importance in therapeutic field. However, remarkable changes in availability values of captopril in presence of different H2 blockers were observed (Table 5) and shows in figures 5 and 6. Hence forth, present results clearly indicated that captopril may interact with H2- receptors antagonists. In conclusion availability of captopril increased due to complex formation with H2-receptor antagonists. Literature survey also reveals the same fact that captopril shows interaction with ranitidine [22]. However, further studies will be conducted to ascertain the chemistry of complexes formed. On the basis of present findings, it is also suggested that these two drugs should not be co administered until extensive in vivo studies ensures that the two co administered drugs does not decreases the therapeutic effects of each other.


Figure 5: After interaction chromatogram showing drift in retention time as well as change in AUC of drugs (Rantidine and captopril).


Figure 6: After interaction chromatogram showing drift in retention time as well as change in AUC of drugs (Famotidine and Captopril).


Our study reveals that the availability of captopril in presence of famotidine and ranitidine increased, which reflects its complexation with these drugs. Moreover, famotidine and ranitidine underwent complexation with captopril more profoundly and intensely compared with cimitidine. It is concluded that coadministration of captopril and H2-receptor antagonists leads to the formation of charge-transfer complex depleting both the interacting drugs to bind to their respective receptors. Furthermore, occurrence of such interactions could impair the clinical efficacy of these drugs and reduce their bioavailability further investigations are required for this purpose.


The authors would like to express gratitude for the Naveed Ahmed Siddiqui for providing the reference substances, and support.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 12511
  • [From(publication date):
    February-2013 - Jul 17, 2019]
  • Breakdown by view type
  • HTML page views : 8701
  • PDF downloads : 3810